首页> 外文期刊>海南医科大学学报(英文版) >Effect of Prednisone and Cyclophosphamide combine with ligustrazine injection on immunologic function and other related factors in patients with systemic lupus erythematosus
【24h】

Effect of Prednisone and Cyclophosphamide combine with ligustrazine injection on immunologic function and other related factors in patients with systemic lupus erythematosus

机译:泼尼松和环磷酰胺联合川li嗪注射液对系统性红斑狼疮患者免疫功能及其他相关因素的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Objective:To investigate the effect of prednisone and cyclophosphamide combine with ligustrazine injection on immunologic function and other related factors in patients with systemic lupus erythematosus (SLE).Methods: The subjects selected 70 patients with SLE who diagnosed and treated in our hospital from March 2014 to May 2018, divided into control group and observation group randomly, 35 cases in each group. The patients in the control group were treated with prednisone combined with cyclophosphamide, and the patients in the observation group was given intravenous drip of ligustrazine injection on the basis of the control group. Before and after treatment, detected and compared the immunologic indexes (IgG, C3, ANA), matrix metalloproteinases (MMP-3, MMP-9, TIMP1), chemotactic factor (CXCL9, CXCL10, CXCL11) and serum levels of IL-10, PRL, S100 protein and EET between the two groups.Results: Before treatments, the immunologic indexes(IgG, C3, ANA), matrix metalloproteinases(MMP-3, MMP-9, TIMP1),chemotactic factor(CXCL9, CXCL10, CXCL11) and serum levels of IL-10, PRL, S100 protein and EET between the two groups had no statistical significance(P>0.05); After treatments, the immunologic indexes (IgG, C3, ANA), matrix metalloproteinases(MMP-3, MMP-9), chemotactic factor (CXCL9, CXCL10, CXCL11) and serum levels of IL-10, PRL, S100 protein and EET between the two groups had statistical significances (P<0.05).Conclusion: Ligustrazine injection was added to SLE patients on the basis of prednisone combined with cyclophosphamide therapy, it not only could significantly improve the immunologic function of patients, but also improve the levels of matrix metalloproteinases, chemokines and related serum factors, it's worthy of clinical research and application.
机译:目的:探讨泼尼松和环磷酰胺联合川li嗪注射液对系统性红斑狼疮(SLE)患者免疫功能及其他相关因素的影响。方法:自2014年3月入选我院诊治的70例SLE患者。至2018年5月,随机分为对照组和观察组,每组35例。对照组患者予泼尼松联合环磷酰胺治疗,观察组在对照组基础上静脉注射川drip嗪注射液。治疗前后,检测并比较免疫指标(IgG,C3,ANA),基质金属蛋白酶(MMP-3,MMP-9,TIMP1),趋化因子(CXCL9,CXCL10,CXCL11)和血清IL-10,两组之间的PRL,S100蛋白和EET结果:治疗前,免疫学指标(IgG,C3,ANA),基质金属蛋白酶(MMP-3,MMP-9,TIMP1),趋化因子(CXCL9,CXCL10,CXCL11)两组患者血清IL-10,PRL,S100蛋白和EET水平无统计学意义(P> 0.05);治疗后,免疫指标(IgG,C3,ANA),基质金属蛋白酶(MMP-3,MMP-9),趋化因子(CXCL9,CXCL10,CXCL11)以及血清IL-10,PRL,S100蛋白和EET水平在两组具有统计学意义(P <0.05)。结论:泼尼松联合环磷酰胺治疗基础上加用川gust嗪注射液治疗SLE患者,不仅可以明显改善患者的免疫功能,而且可以提高基质水平金属蛋白酶,趋化因子及相关血清因子,值得临床研究和应用。

著录项

  • 来源
    《海南医科大学学报(英文版)》 |2019年第11期|33-37|共5页
  • 作者

    Zhi-Min Lyu; Jing Gu; Li-Ping Ye;

  • 作者单位

    Department of Rheumatism for Nephropathy, The first people's Hospital of Chuzhou, Chuzhou, 239000, Anhui Province, China;

    Department of Rheumatism for Nephropathy, The first people's Hospital of Chuzhou, Chuzhou, 239000, Anhui Province, China;

    Department of Rheumatism for Nephropathy, The first people's Hospital of Chuzhou, Chuzhou, 239000, Anhui Province, China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号